CA1165241A - Sustained release theophylline tablet having reduced bulk - Google Patents

Sustained release theophylline tablet having reduced bulk

Info

Publication number
CA1165241A
CA1165241A CA000376477A CA376477A CA1165241A CA 1165241 A CA1165241 A CA 1165241A CA 000376477 A CA000376477 A CA 000376477A CA 376477 A CA376477 A CA 376477A CA 1165241 A CA1165241 A CA 1165241A
Authority
CA
Canada
Prior art keywords
theophylline
tablet
pharmaceutical tablet
weight
magnesium stearate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000376477A
Other languages
English (en)
French (fr)
Inventor
Claude E. Gallian
Dana Brooke
Stephen T. David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of CA1165241A publication Critical patent/CA1165241A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA000376477A 1980-05-06 1981-04-29 Sustained release theophylline tablet having reduced bulk Expired CA1165241A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14742980A 1980-05-06 1980-05-06
US147,429 1980-05-06
US24978781A 1981-04-01 1981-04-01
US249,787 1981-04-01

Publications (1)

Publication Number Publication Date
CA1165241A true CA1165241A (en) 1984-04-10

Family

ID=26844921

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000376477A Expired CA1165241A (en) 1980-05-06 1981-04-29 Sustained release theophylline tablet having reduced bulk

Country Status (17)

Country Link
AT (1) AT380789B (enExample)
AU (1) AU549299B2 (enExample)
CA (1) CA1165241A (enExample)
CY (1) CY1368A (enExample)
DE (1) DE3117756A1 (enExample)
DK (1) DK155976C (enExample)
FI (1) FI811356L (enExample)
FR (1) FR2484253A1 (enExample)
GB (1) GB2078518B (enExample)
HK (1) HK4288A (enExample)
IE (1) IE51157B1 (enExample)
IT (1) IT1209867B (enExample)
KE (1) KE3722A (enExample)
LU (1) LU83342A1 (enExample)
NL (1) NL8102168A (enExample)
SE (1) SE452550B (enExample)
SG (1) SG30987G (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
FR2595945B1 (fr) * 1986-03-19 1990-01-19 Doms Laboratoires Comprime-retard de theophylline a base de p.v.c., et son procede de preparation
USD557612S1 (en) * 2006-04-10 2007-12-18 Parfums Christian Dior Flask for a cosmetic product

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE636568A (enExample) * 1961-01-31
DE1228029C2 (de) * 1964-05-09 1973-05-17 Merck Ag E Verfahren zur Herstellung von Tabletten durch Pressen von Pulvergemischen ohne vorhergehende Granulation
US3723614A (en) * 1971-01-06 1973-03-27 Ciba Geigy Ag Maltese-cross scored tablet
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion

Also Published As

Publication number Publication date
AT380789B (de) 1986-07-10
FR2484253B1 (enExample) 1983-06-03
DE3117756C2 (enExample) 1992-11-26
SE452550B (sv) 1987-12-07
KE3722A (en) 1987-04-30
AU549299B2 (en) 1986-01-23
DE3117756A1 (de) 1982-04-29
IT8148406A0 (it) 1981-05-06
GB2078518B (en) 1984-04-11
DK200181A (da) 1981-11-07
AU7020581A (en) 1981-11-12
IT1209867B (it) 1989-08-30
SE8102814L (sv) 1981-11-07
FR2484253A1 (fr) 1981-12-18
LU83342A1 (fr) 1982-01-20
FI811356A7 (fi) 1981-11-07
DK155976C (da) 1989-10-30
SG30987G (en) 1987-07-17
ATA202081A (de) 1985-12-15
IE51157B1 (en) 1986-10-15
CY1368A (en) 1987-08-07
FI811356L (fi) 1981-11-07
IE810989L (en) 1981-11-06
DK155976B (da) 1989-06-12
GB2078518A (en) 1982-01-13
HK4288A (en) 1988-01-29
NL8102168A (nl) 1981-12-01

Similar Documents

Publication Publication Date Title
US4465660A (en) Sustained release tablet containing at least 95 percent theophylline
EP0231826B1 (en) Theophylline sustained release tablet
US4443428A (en) Extended action controlled release compositions
EP0635265B1 (en) Controlled release pharmaceutical compositions based on one or more pharmaceutically acceptable salts of gamma hydroxy-butyric acid
EP0656775B1 (en) Sustained release tablets containing bupropion
EP1242091B1 (en) Use of pharmaceutical compositions comprising oxcarbazepine in the fasted state
AU764742B2 (en) Dispersible compositions containing L-DOPA ethyl ester
CA2042289C (en) Taste masking and sustained release coatings for pharmaceuticals
US4547358A (en) Sustained release tablet containing at least 95 percent theophylline
CA1200496A (en) Oral dipyridamole forms
US4900558A (en) Sustained release ibuprofen formulation including a core of ibuprofen and a microcrystalline cellulose and a covering of acrylic polymer and hydroxylated cellulose derivative
EP0142561A1 (en) Long-acting nifedipine preparation
CA1261268A (en) Theophylline sustained release formulation
CY1368A (en) Sustained release theophylline tablet having reduced bulk
Hutchison et al. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia
GB2164556A (en) Sustained release pharmaceutical tablet of theophylline and production process therefor
Jonkman Food interactions with once-a-day theophylline preparations: a review
Ellis et al. Effectiveness of generic acetazolamide
JPH0136444B2 (enExample)
Sahoo et al. FORMULATION AND EVALUATION OF ORODISPERSIBLE TABLETS OF GRANISETRON HYDROCHLORIDE USING PLANTAGO OVATE AS NATURAL SUPERDISINTEGRANTS.
KR950007229B1 (ko) 케토티펜을 함유한 약학적 조성물
Alagarsamy et al. FORMULATION AND EVALUATION OF ORODISPERSIBLE TABLETS OF GRANISETRON HYDROCHLORIDE USING PLANTAGO OVATE AS NATURAL SUPERDISINTEGRANTS
JPS61152629A (ja) 徐放性テオフィリン調剤及びその製法
Shenfield et al. Effect of food and tablet division on the absorption of a sustained‐release preparation of theophylline
PL203547B1 (pl) Kompozycje gliburidu

Legal Events

Date Code Title Description
MKEX Expiry